Orchid Pharma and Cipla Collaborate on New Antibiotic Launch

Orchid Pharma Limited announced in a stock exchange filing the launch of its new drug, Cefepime-Enmetazobactam, approved for treating complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). In a landmark collaboration, Orchid Pharma has partnered with Cipla Limited to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.

The company stated that the launch of Cefepime-Enmetazobactam represents a significant milestone for India’s pharmaceutical industry in the fight against antimicrobial resistance (AMR), reinforcing the country’s leadership in medical innovation. Orchid Pharma and Cipla are confident that this collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research.

The partnership combines Orchid Pharma’s innovative drug development capabilities with Cipla’s extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India quickly and efficiently.

Commenting on the launch, the Managing Director of Orchid Pharma, Mr Manish Dhanuka, said, “With increasing resistance to the current drugs most commonly used for the treatment of these indications – e.g. Piperacillin-Tazobactam for cUTI – doctors were forced to start using Carbapenems – a reserve drug meant to be used when most other drugs don’t work. Now, Orchid’s CefepimeEnmetazobactam will allow doctors to spare Carbapenems, prolonging their effective life by restricting their use.”

The Managing Director and Global Chief Executive Officer of Cipla, Mr Umang Vohra, said, “AMR is an urgent and serious healthcare challenge that needs global attention. With the rising incidence of potentially-life threatening infections, there is a strong need for novel anti-infectives in the effective treatment of MDR infections. This partnership enhances Cipla’s commitment to AMR stewardship and strengthens our efforts to combat infectious diseases and deliver advanced, innovative therapies to patients.”

Orchid Pharma further added that both companies are committed to responsible antibiotic stewardship and will work closely with healthcare professionals to ensure the proper use of this new antibiotic combination. Educational initiatives and guidelines for prescribing will be developed to maximise the drug’s benefits while minimising the risk of further antimicrobial resistance.

About Orchid Pharma Ltd

Orchid Pharma Ltd (Orchid) is a vertically integrated company that spans the entire pharmaceutical value chain. It has established credentials in research, manufacturing, and marketing.

On July 1, 2024, the share price of Orchid Pharma Ltd opened at ₹1,156.00, touching the day’s high at ₹1,193.20, as of 10:21 AM on the NSE.

About Cipla Ltd

Cipla is a global pharmaceutical company specialising in complex generics and expanding its portfolio across key markets such as India, South Africa, North America, and other regulated and emerging markets.

On July 1, 2024, the share price of Cipla Ltd opened at ₹1,484.95, touching the day’s high at ₹1,493.70, as of 10:22 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.